ValiRx PLC Directorate Change (0665A)
18 Enero 2024 - 1:00AM
UK Regulatory
TIDMVAL
RNS Number : 0665A
ValiRx PLC
18 January 2024
18 January 2024
VALIRX PLC
("ValiRx" or the "Company")
Directorate Change
ValiRx plc (the "Company") (AIM: VAL), a life sciences company
focusing on early-stage cancer therapeutics and women's health,
announces the resignation of Stella Panu as a Non-Executive
Director of the Company, effective from 15 April 2024.
Following the fundraise in January 2024, Stella has decided to
step down from the Board of ValiRx to concentrate on her other
commitments. Stella has agreed to a 3-month handover period to
allow sufficient time for the Board to identify an appropriate
replacement and ensure a smooth transition of responsibilities.
During Stella's tenure as a Non-Executive Director, she has made
significant contributions to the development of the strategy and
the changes required to ensure the Company achieves its longer-term
growth goals. Stella's expertise and guidance have been invaluable,
and the Company would like to express its gratitude for her
dedicated service.
With Stella's support, the Company will be working diligently to
identify a suitable candidate to fill the vacancy created by her
departure. In particular, the Board will be seeking candidates with
a background in early-stage pharmaceutical development, aligning
with our strategic focus. The Board and management are committed to
ensuring a seamless transition and will work closely with Stella to
facilitate a comprehensive handover of duties.
Kevin Cox, Chairman of ValiRx commented "I would very much like
to extend my sincere appreciation to Stella for her invaluable
contributions to ValiRx over the past years. Her knowledge and
skills have been instrumental in the successful acquisition of
Imagen Therapeutics assets, which have provided a significant
milestone in the development of Inaphaea Biolabs. Her presence on
the Board and guidance to me will be greatly missed, and I wish her
continued success in future endeavours."
The Directors of the Company take responsibility for this
announcement.
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz
Lucy Wharton - Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
--------------------------
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray/Jo Turner/Ludovico Lazzaretti
--------------------------
Cavendish Capital Markets Limited Tel: +44 (0) 20 7397
(Joint Broker) 8900
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate
Finance)
--------------------------
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657
James Pope / Andy Thacker 0050
--------------------------
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer
therapeutics and women's health, accelerating the translation of
innovative science into impactful medicines to improve patient
lives.
ValiRx provides the scientific, financial, and commercial
framework for enabling rapid translation of innovative science into
clinical development.
Using its extensive and proven experience in research and drug
development, the team at ValiRx selects and incubates promising
novel drug candidates and guides them through an optimised process
of development, from pre-clinical studies to clinic and
investor-ready assets.
ValiRx connects diverse disciplines across scientific,
technical, and commercial domains, with the aim of achieving a more
streamlined, less costly, drug development process. The team works
closely with carefully selected collaborators and leverages the
combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or
partnered with investors through ValiRx subsidiary companies for
further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
Cautionary statement
Certain statements made in this announcement are forward-looking
statements. Such statements are based on current expectations and
assumptions and are subject to a number of risks and uncertainties
that could cause actual events or results to differ materially from
any expected future events or results expressed or implied in these
forward-looking statements. Persons receiving this announcement
should not place undue reliance on forward-looking statements.
Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new
information, future developments or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGPUWAGUPCGMM
(END) Dow Jones Newswires
January 18, 2024 02:00 ET (07:00 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De May 2023 a May 2024
